Barinthus Biotherapeutics’ (BRNS) “Buy” Rating Reiterated at HC Wainwright

by · The Cerbat Gem

HC Wainwright restated their buy rating on shares of Barinthus Biotherapeutics (NASDAQ:BRNS – Free Report) in a report released on Thursday, Benzinga reports. They currently have a $5.00 price target on the stock.

Several other analysts have also recently issued reports on BRNS. William Blair reaffirmed an outperform rating on shares of Barinthus Biotherapeutics in a research note on Thursday, June 13th. Alliance Global Partners cut their price target on Barinthus Biotherapeutics from $11.00 to $9.50 and set a buy rating for the company in a report on Tuesday, August 13th. Finally, Barclays reduced their price objective on Barinthus Biotherapeutics from $7.00 to $3.00 and set an overweight rating on the stock in a research report on Thursday, June 13th.

Check Out Our Latest Stock Report on Barinthus Biotherapeutics

Barinthus Biotherapeutics Price Performance

NASDAQ BRNS opened at $1.18 on Thursday. The stock’s 50 day simple moving average is $1.31 and its 200-day simple moving average is $1.86. The company has a market cap of $46.52 million, a PE ratio of -0.64 and a beta of -0.53. Barinthus Biotherapeutics has a 1-year low of $1.11 and a 1-year high of $5.10.

Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.01). On average, equities research analysts anticipate that Barinthus Biotherapeutics will post -1.71 EPS for the current fiscal year.

Hedge Funds Weigh In On Barinthus Biotherapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Catalina Capital Group LLC acquired a new stake in shares of Barinthus Biotherapeutics during the 2nd quarter worth approximately $25,000. Ipswich Investment Management Co. Inc. acquired a new stake in Barinthus Biotherapeutics during the second quarter worth $32,000. BlueCrest Capital Management Ltd purchased a new stake in Barinthus Biotherapeutics in the first quarter valued at $1,292,000. DC Funds LP acquired a new position in shares of Barinthus Biotherapeutics in the 1st quarter valued at $1,528,000. Finally, Alphabet Inc. purchased a new position in shares of Barinthus Biotherapeutics during the 2nd quarter worth $2,119,000. 25.20% of the stock is currently owned by institutional investors and hedge funds.

About Barinthus Biotherapeutics

(Get Free Report)

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.

Read More